ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
71,114.35
-0.47%
S&P 500
5,308.13
0.09%
Dow Jones
39,806.77
0.00%
US Dollar vs Yen
156.2775
-0.06%
Brent Oil
82.145
-1.66%
Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Aura Biosciences Inc (AURA)

  7. Aura Biosciences Inc (AURA) ニュース

AURA

Aura Biosciences (AURA)

Aura Biosciences Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:AURA
日付受信時刻ニュースソース見出しコード企業名
2024/05/0920 : 10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AURAAura Biosciences Inc
2024/05/0920 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AURAAura Biosciences Inc
2024/05/0920 : 00GlobeNewswire Inc.Aura Biosciences Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:AURAAura Biosciences Inc
2024/05/0820 : 00GlobeNewswire Inc.Aura Biosciences to Participate in Upcoming Investor ConferencesNASDAQ:AURAAura Biosciences Inc
2024/03/2720 : 00Business WireAura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsNASDAQ:AURAAura Biosciences Inc
2024/03/0507 : 35Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AURAAura Biosciences Inc
2024/02/2621 : 00Business WireAura Biosciences to Participate in Upcoming Investor ConferencesNASDAQ:AURAAura Biosciences Inc
2024/02/2406 : 22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AURAAura Biosciences Inc
2024/02/0306 : 01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AURAAura Biosciences Inc
2024/02/0306 : 01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AURAAura Biosciences Inc
2024/02/0306 : 01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AURAAura Biosciences Inc
2024/01/2506 : 20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AURAAura Biosciences Inc
2024/01/2506 : 18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AURAAura Biosciences Inc
2024/01/2506 : 01Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AURAAura Biosciences Inc
2024/01/2506 : 01Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AURAAura Biosciences Inc
2024/01/0906 : 11Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AURAAura Biosciences Inc
2024/01/0821 : 31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AURAAura Biosciences Inc
2024/01/0306 : 29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AURAAura Biosciences Inc
2023/12/1606 : 30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AURAAura Biosciences Inc
2023/12/0722 : 00Business WireAura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal MelanomaNASDAQ:AURAAura Biosciences Inc
2023/11/1007 : 02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AURAAura Biosciences Inc
2023/11/1006 : 15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AURAAura Biosciences Inc
2023/11/1006 : 05Business WireAura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational HighlightsNASDAQ:AURAAura Biosciences Inc
2023/11/0821 : 00Business WireAura Biosciences to Participate in Upcoming Investor ConferencesNASDAQ:AURAAura Biosciences Inc
2023/11/0808 : 19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AURAAura Biosciences Inc
2023/11/0808 : 09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AURAAura Biosciences Inc
2023/11/0806 : 55Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AURAAura Biosciences Inc
2023/11/0712 : 02Business WireAura Biosciences Announces Pricing of Public Offering of Common StockNASDAQ:AURAAura Biosciences Inc
2023/11/0706 : 22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AURAAura Biosciences Inc
2023/11/0706 : 20Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AURAAura Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:AURA

最近閲覧した銘柄

PM
XAUUSD
Gold vs US Dollar
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
MRK
Merck
NASDAQ
GOOGL
Alphabet
NYSE
JPM
JP Morgan Chase
AMEX
SPY
SPDR S&P 500
AMEX
XLE
Energy Select Sector SPDR
USI
USTECH100
US Tech 100
NASDAQ
MSFT
Microsoft
NYSE
KO
Coca Cola
COIN
ETHUSD
Ethereum
AMEX
XLV
Health Care Select Sector
CCOM
US30
US 30
CCOM
US100
US Tech 100
NYSE
AXP
American Express
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有